T. Rowe Price Associates
ODT

T. Rowe Price Associates’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

T. Rowe Price Associates’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-114,265
Closed -$2.19M – 2888
2020
Q4 		$2.19M Sell
114,265
-345,894
-75% -$5.34M ﹤0.01% 1604
2020
Q3 		$6.18M Sell
460,159
-568,979
-55% -$16.1M ﹤0.01% 1377
2020
Q2 		$43.6M Sell
1,029,138
-42,079
-4% -$1.36M 0.01% 893
2020
Q1 		$29.6M Sell
1,071,217
-2,764
-0.3% -$80.6K ﹤0.01% 945
2019
Q4 		$34.9M Buy
1,073,981
+7,661
+0.7% +$237K ﹤0.01% 1024
2019
Q3 		$27.8M Buy
1,066,320
+23,874
+2% +$799K ﹤0.01% 1050
2019
Q2 		$38.2M Buy
1,042,446
+672,721
+182% +$16.1M 0.01% 980
2019
Q1 		$8.18M Buy
369,725
+100
+0% +$1.75K ﹤0.01% 1346
2018
Q4 		$5.2M Buy
369,625
+118,954
+47% +$1.85M ﹤0.01% 1397
2018
Q3 		$4.87M Buy
+250,671
New +$5.11M ﹤0.01% 1459

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

T. Rowe Price Associates's ODT Position: Q1 2021 in Review

T. Rowe Price Associates sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2021, closing a stake of 114,265 shares — an estimated $2.19M sold.

T. Rowe Price Associates first reported a position in ODT in Q3 2018 and held it in 10 quarters. The position peaked at $43.6M in Q2 2020. 83 funds tracked by Wall St. Rank hold ODT as of Q1 2021.

  • T. Rowe Price Associates reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 114,265 Odonate Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2.19M.
  • T. Rowe Price Associates first reported a position in Odonate Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
  • T. Rowe Price Associates's Odonate Therapeutics, Inc. Common Stock position peaked at $43.6M in Q2 2020.
  • 83 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2021.

Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.